H. Lundbeck AS (STU:LDBA) Beneish M-Score: -2.48 (As of Jul. 04, 2026)


STU:LDBA H. Lundbeck AS STU:LDBA
68 GF Score
Price €5.75
GF Value €6.36
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is H. Lundbeck AS Beneish M-Score?

H. Lundbeck AS STU:LDBA -2.46% 68 Beneish M-Score is -2.48 as of Jul. 04, 2026. GuruFocus rates STU:LDBA with a GF Score™ of 68/100 and a GF Value™ of €6.36 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 909 Drug Manufacturers companies, H. Lundbeck AS ranks worse than 51.71% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.48 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for H. Lundbeck AS's Beneish M-Score or its related term are showing as below:

STU:LDBA' s Beneish M-Score Range Over the Past 10 Years
Min: -3.38   Med: -2.68   Max: -2.15
Current: -2.48

During the past 13 years, the highest Beneish M-Score of H. Lundbeck AS was -2.15. The lowest was -3.38. And the median was -2.68.


H. Lundbeck AS Beneish M-Score Historical Data

* Premium members only.

The historical data trend for H. Lundbeck AS's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

H. Lundbeck AS Beneish M-Score Chart

H. Lundbeck AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.78 -2.46 -2.67 -2.42 -2.59

H. Lundbeck AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.21 -2.27 -2.15 -2.59 -2.48

STU:LDBA vs ZTS, UTHR, VTRS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


H. Lundbeck AS Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where H. Lundbeck AS's Beneish M-Score falls into.


STU:LDBA
68GF Score
H. Lundbeck AS STU:LDBA
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

H. Lundbeck AS Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of H. Lundbeck AS for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0225+0.528 * 0.9855+0.404 * 0.9703+0.892 * 1.1107+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8407+4.679 * -0.033528-0.327 * 0.9064
=-2.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €815 Mil.
Revenue was 953.262 + 815.788 + 841.281 + 807.35 = €3,418 Mil.
Gross Profit was 779.2 + 649.23 + 727.931 + 661.108 = €2,817 Mil.
Total Current Assets was €1,692 Mil.
Total Assets was €6,998 Mil.
Property, Plant and Equipment(Net PPE) was €400 Mil.
Depreciation, Depletion and Amortization(DDA) was €0 Mil.
Selling, General, & Admin. Expense(SGA) was €1,223 Mil.
Total Current Liabilities was €1,203 Mil.
Long-Term Debt & Capital Lease Obligation was €1,452 Mil.
Net Income was 221.826 + -3.615 + 147.516 + 129.487 = €495 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = €0 Mil.
Cash Flow from Operations was 80.141 + 123.312 + 308.028 + 218.359 = €730 Mil.
Total Receivables was €718 Mil.
Revenue was 835.936 + 742.991 + 767.419 + 730.621 = €3,077 Mil.
Gross Profit was 690.603 + 599.381 + 620.695 + 589.133 = €2,500 Mil.
Total Current Assets was €1,590 Mil.
Total Assets was €7,269 Mil.
Property, Plant and Equipment(Net PPE) was €427 Mil.
Depreciation, Depletion and Amortization(DDA) was €0 Mil.
Selling, General, & Admin. Expense(SGA) was €1,309 Mil.
Total Current Liabilities was €1,018 Mil.
Long-Term Debt & Capital Lease Obligation was €2,025 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(815.056 / 3417.681) / (717.685 / 3076.967)
=0.238482 / 0.233244
=1.0225

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2499.812 / 3076.967) / (2817.469 / 3417.681)
=0.812427 / 0.82438
=0.9855

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1692.057 + 399.634) / 6997.947) / (1 - (1589.687 + 427.152) / 7269.227)
=0.701099 / 0.722551
=0.9703

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3417.681 / 3076.967
=1.1107

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 427.152)) / (0 / (0 + 399.634))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1222.635 / 3417.681) / (1309.283 / 3076.967)
=0.357738 / 0.425511
=0.8407

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1452.169 + 1202.916) / 6997.947) / ((2025.017 + 1017.737) / 7269.227)
=0.379409 / 0.41858
=0.9064

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(495.214 - 0 - 729.84) / 6997.947
=-0.033528

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

H. Lundbeck AS has a M-score of -2.48 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.48 mean?
H. Lundbeck AS (STU:LDBA) has a Beneish M-Score of -2.48 as of Jul. 04, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on H. Lundbeck AS and its competitors. According to the industry distribution chart, H. Lundbeck AS ranks #470 out of 909 companies in the Drug Manufacturers industry, placing it in the top 51.7%.
Is H. Lundbeck AS's Beneish M-Score too high?
H. Lundbeck AS's current Beneish M-Score is -2.48. Based on the distribution chart, H. Lundbeck AS ranks #470 out of 909 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, H. Lundbeck AS has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does H. Lundbeck AS's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, H. Lundbeck AS ranks #470 out of 909 companies for Beneish M-Score. This places H. Lundbeck AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on H. Lundbeck AS and its competitors. H. Lundbeck AS's current Beneish M-Score is -2.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H. Lundbeck AS stock overvalued right now?
Based on GuruFocus' analysis, H. Lundbeck AS (STU:LDBA) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.36, compared to a current price of €5.75 — trading 9.6% below its estimated fair value. The current Beneish M-Score is -2.48. H. Lundbeck AS's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For H. Lundbeck AS (STU:LDBA), the current Beneish M-Score is -2.48 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is H. Lundbeck AS (STU:LDBA) Overvalued in 2026?

Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued. The current stock price of €5.75 is trading 9.6% below its estimated GF Value™ of €6.36. GuruFocus considers H. Lundbeck AS to be Modestly Undervalued.

Key valuation signals for STU:LDBA:

  • Beneish M-Score: -2.48
  • GF Value™: €6.36 vs. price of €5.75 (9.6% below fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the STU:LDBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


H. Lundbeck AS Business Description

Address Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
68GF Score

Get the complete analysis for STU:LDBA

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.75
Price
€6.36
GF Value